Wedge Capital Management L L P NC Acquires New Stake in Collegium Pharmaceutical, Inc. $COLL

Wedge Capital Management L L P NC acquired a new stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 58,261 shares of the specialty pharmaceutical company’s stock, valued at approximately $2,697,000. Wedge Capital Management L L P NC owned about 0.18% of Collegium Pharmaceutical at the end of the most recent quarter.

Other institutional investors have also recently modified their holdings of the company. Illinois Municipal Retirement Fund boosted its stake in shares of Collegium Pharmaceutical by 1.6% in the 3rd quarter. Illinois Municipal Retirement Fund now owns 17,281 shares of the specialty pharmaceutical company’s stock worth $605,000 after buying an additional 278 shares during the last quarter. Vident Advisory LLC increased its position in Collegium Pharmaceutical by 1.9% during the third quarter. Vident Advisory LLC now owns 15,466 shares of the specialty pharmaceutical company’s stock valued at $541,000 after acquiring an additional 281 shares during the last quarter. GAMMA Investing LLC lifted its holdings in Collegium Pharmaceutical by 9.6% in the fourth quarter. GAMMA Investing LLC now owns 3,262 shares of the specialty pharmaceutical company’s stock valued at $151,000 after acquiring an additional 285 shares during the period. Federated Hermes Inc. lifted its holdings in Collegium Pharmaceutical by 67.0% in the third quarter. Federated Hermes Inc. now owns 872 shares of the specialty pharmaceutical company’s stock valued at $31,000 after acquiring an additional 350 shares during the period. Finally, Assetmark Inc. boosted its position in Collegium Pharmaceutical by 8.4% in the third quarter. Assetmark Inc. now owns 4,551 shares of the specialty pharmaceutical company’s stock worth $159,000 after purchasing an additional 352 shares during the last quarter.

Collegium Pharmaceutical Stock Performance

NASDAQ:COLL opened at $32.44 on Monday. The stock has a 50-day moving average price of $41.91 and a 200 day moving average price of $41.74. The stock has a market capitalization of $1.03 billion, a P/E ratio of 18.97 and a beta of 0.67. Collegium Pharmaceutical, Inc. has a 12-month low of $23.23 and a 12-month high of $50.79. The company has a current ratio of 1.57, a quick ratio of 1.48 and a debt-to-equity ratio of 2.59.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings results on Thursday, February 26th. The specialty pharmaceutical company reported $2.04 EPS for the quarter, missing analysts’ consensus estimates of $2.20 by ($0.16). Collegium Pharmaceutical had a net margin of 8.05% and a return on equity of 98.65%. The firm had revenue of $205.45 million for the quarter, compared to the consensus estimate of $206.36 million. During the same period in the previous year, the company posted $1.77 earnings per share. Collegium Pharmaceutical’s quarterly revenue was up 12.9% on a year-over-year basis. Equities research analysts forecast that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently commented on COLL shares. Barclays reduced their price target on shares of Collegium Pharmaceutical from $58.00 to $56.00 and set an “overweight” rating for the company in a research report on Friday, January 9th. Needham & Company LLC reaffirmed a “buy” rating and set a $56.00 target price (up from $54.00) on shares of Collegium Pharmaceutical in a report on Thursday, March 19th. Truist Financial set a $58.00 price target on shares of Collegium Pharmaceutical in a research report on Tuesday, February 10th. Zacks Research cut shares of Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 6th. Finally, Wall Street Zen lowered Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 28th. Four equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $53.40.

Insider Transactions at Collegium Pharmaceutical

In other news, EVP Scott Dreyer sold 49,976 shares of the firm’s stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $40.41, for a total value of $2,019,530.16. Following the completion of the sale, the executive vice president directly owned 71,770 shares of the company’s stock, valued at $2,900,225.70. This trade represents a 41.05% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP David Dieter sold 13,976 shares of Collegium Pharmaceutical stock in a transaction that occurred on Wednesday, March 18th. The stock was sold at an average price of $34.92, for a total value of $488,041.92. Following the completion of the transaction, the executive vice president owned 77,071 shares of the company’s stock, valued at approximately $2,691,319.32. This trade represents a 15.35% decrease in their position. The SEC filing for this sale provides additional information. 2.51% of the stock is currently owned by company insiders.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.